CM Hospitalar S/A Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

CM Hospitalar S/A wird ein jährliches Gewinn- und Umsatzwachstum von 71.2% bzw. 6.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 83.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.6% betragen.

Wichtige Informationen

71.2%

Wachstumsrate der Gewinne

83.6%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	26.6%
Wachstumsrate der Einnahmen	6.8%
Zukünftige Eigenkapitalrendite	6.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

There Is A Reason CM Hospitalar S/A's (BVMF:VVEO3) Price Is Undemanding

Oct 17

Capital Allocation Trends At CM Hospitalar S/A (BVMF:VVEO3) Aren't Ideal

Jul 30

CM Hospitalar S/A (BVMF:VVEO3) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough

Jun 25

CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%

May 11

CM Hospitalar S/A (BVMF:VVEO3) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 01

Analysts Are Updating Their CM Hospitalar S/A (BVMF:VVEO3) Estimates After Its Annual Results

Mar 29

Why Investors Shouldn't Be Surprised By CM Hospitalar S/A's (BVMF:VVEO3) 28% Share Price Plunge

Mar 27

Here's Why CM Hospitalar S/A (BVMF:VVEO3) Has A Meaningful Debt Burden

Jan 15

Here's What To Make Of CM Hospitalar S/A's (BVMF:VVEO3) Decelerating Rates Of Return

Dec 14

CM Hospitalar S/A (BVMF:VVEO3) Has More To Do To Multiply In Value Going Forward

Jun 07

Returns On Capital Signal Tricky Times Ahead For CM Hospitalar S/A (BVMF:VVEO3)

Jan 16

Be Wary Of CM Hospitalar S/A (BVMF:VVEO3) And Its Returns On Capital

Aug 31

Statutory Earnings May Not Be The Best Way To Understand CM Hospitalar S/A's (BVMF:VVEO3) True Position

May 17

Pinning Down CM Hospitalar S/A's (BVMF:VVEO3) P/E Is Difficult Right Now

Dec 09

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:VVEO3 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (BRL Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	13,737	252	565	349	7
12/31/2025	12,775	121	-7,531	297	9
12/31/2024	11,746	N/A	1,027	158	2
9/30/2024	11,570	-61	-175	69	N/A
6/30/2024	11,462	183	-544	-273	N/A
3/31/2024	11,242	326	-662	-372	N/A
12/31/2023	11,084	360	-1,198	-896	N/A
9/30/2023	10,805	162	-142	170	N/A
6/30/2023	10,234	209	-122	173	N/A
3/31/2023	9,647	200	-222	52	N/A
12/31/2022	8,747	260	273	533	N/A
9/30/2022	7,741	278	140	329	N/A
6/30/2022	6,963	286	-17	136	N/A
3/31/2022	6,634	458	79	213	N/A
12/31/2021	6,219	395	194	320	N/A
9/30/2021	6,031	372	102	189	N/A
6/30/2021	5,746	337	N/A	N/A	N/A
3/31/2021	5,055	136	88	158	N/A
12/31/2020	4,413	122	132	186	N/A
12/31/2019	3,003	36	137	163	N/A
12/31/2018	2,641	34	58	86	N/A
12/31/2017	1,696	59	N/A	54	N/A
12/31/2016	1,148	165	N/A	59	N/A
12/31/2015	998	-1	N/A	-27	N/A
12/31/2014	866	3	N/A	-82	N/A
12/31/2013	720	3	N/A	16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VVEO3 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (10.4%).

Ertrag vs. Markt: VVEO3 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: VVEO3 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: VVEO3Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (7.3% pro Jahr).

Hohe Wachstumseinnahmen: VVEO3Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VVEO3Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.6%).

CM Hospitalar S/A Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 10% to R$8.63

Consensus EPS estimates fall by 23%

Consensus EPS estimates fall by 418%

Price target decreased by 12% to R$8.77

Consensus EPS estimates fall from profit to R$0.0073 loss

Price target decreased by 28% to R$11.01

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to R$8.63

There Is A Reason CM Hospitalar S/A's (BVMF:VVEO3) Price Is Undemanding

Consensus EPS estimates fall by 23%

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 418%

Price target decreased by 12% to R$8.77

Investor sentiment deteriorates as stock falls 23%

Second quarter 2024 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Capital Allocation Trends At CM Hospitalar S/A (BVMF:VVEO3) Aren't Ideal

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 19%

CM Hospitalar S/A (BVMF:VVEO3) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough

Consensus EPS estimates fall from profit to R$0.0073 loss

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 25%

Price target decreased by 28% to R$11.01

Now 28% undervalued after recent price drop

New major risk - Revenue and earnings growth

CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%

First quarter 2024 earnings released: EPS: R$0.01 (vs R$0.13 in 1Q 2023)

Price target decreased by 7.1% to R$15.33

Consensus EPS estimates fall by 11%

CM Hospitalar S/A (BVMF:VVEO3) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Analysts Are Updating Their CM Hospitalar S/A (BVMF:VVEO3) Estimates After Its Annual Results

New major risk - Share price stability

Why Investors Shouldn't Be Surprised By CM Hospitalar S/A's (BVMF:VVEO3) 28% Share Price Plunge

Full year 2023 earnings released: EPS: R$1.20 (vs R$0.92 in FY 2022)

Consensus EPS estimates fall by 10%

Price target decreased by 9.5% to R$22.11

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 8.4% to R$23.89

Here's Why CM Hospitalar S/A (BVMF:VVEO3) Has A Meaningful Debt Burden

Here's What To Make Of CM Hospitalar S/A's (BVMF:VVEO3) Decelerating Rates Of Return

Price target decreased by 7.7% to R$25.61

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: R$0.021 (vs R$0.19 in 3Q 2022)

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: Revenues miss analyst expectations

Price target increased by 7.0% to R$26.26

Consensus EPS estimates fall by 14%

CM Hospitalar S/A (BVMF:VVEO3) Has More To Do To Multiply In Value Going Forward

First quarter 2023 earnings released: EPS: R$0.13 (vs R$0.34 in 1Q 2022)

Consensus EPS estimates fall by 13%

Full year 2022 earnings released

Returns On Capital Signal Tricky Times Ahead For CM Hospitalar S/A (BVMF:VVEO3)

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Be Wary Of CM Hospitalar S/A (BVMF:VVEO3) And Its Returns On Capital

CM Hospitalar S/A (BOVESPA:VVEO3) agreed to acquire Neve Industria e Comercio de Produtos Cirurgicos and Nutrifica Comercio de Nutricao Enteral e Parenteral for BRL 110 million.

Second quarter 2022 earnings: EPS misses analyst expectations

Statutory Earnings May Not Be The Best Way To Understand CM Hospitalar S/A's (BVMF:VVEO3) True Position

First quarter 2022 earnings: Revenues exceed analyst expectations

Upcoming dividend of R$0.16 per share

Full year 2021 earnings: Revenues exceed analyst expectations

Consensus forecasts updated

Investor sentiment improved over the past week

Pinning Down CM Hospitalar S/A's (BVMF:VVEO3) P/E Is Difficult Right Now

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite